DekaBank Deutsche Girozentrale’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,579
Closed -$743K 1329
2021
Q4
$743K Buy
4,579
+797
+21% +$128K ﹤0.01% 1014
2021
Q3
$561K Sell
3,782
-15,091
-80% -$3.14M ﹤0.01% 1024
2021
Q2
$4.61M Buy
18,873
+1,139
+6% +$299K 0.01% 539
2021
Q1
$4.58M Buy
17,734
+5,642
+47% +$1.59M 0.02% 507
2020
Q4
$3.48M Buy
12,092
+6,281
+108% +$1.61M 0.01% 536
2020
Q3
$1.34M Buy
5,811
+1,661
+40% +$378K 0.01% 684
2020
Q2
$816K Sell
4,150
-133
-3% -$24.8K 0.01% 701
2020
Q1
$757K Sell
4,283
-2,421
-36% -$431K 0.01% 669
2019
Q4
$1.1M Sell
6,704
-1,646
-20% -$245K 0.01% 667
2019
Q3
$1.08M Buy
8,350
+150
+2% +$19.5K 0.01% 651
2019
Q2
$981K Buy
8,200
+4,600
+128% +$546K ﹤0.01% 792
2019
Q1
$441K Buy
3,600
+2,600
+260% +$326K ﹤0.01% 927
2018
Q4
$114K Sell
1,000
-2,600
-72% -$306K ﹤0.01% 1046
2018
Q3
$441K Sell
3,600
-6,800
-65% -$751K ﹤0.01% 948
2018
Q2
$894K Buy
10,400
+6,700
+181% +$492K 0.01% 772
2018
Q1
$223K Buy
+3,700
New +$211K ﹤0.01% 980

Other funds holding AMED

DekaBank Deutsche Girozentrale's AMED Position: Q1 2022 in Review

DekaBank Deutsche Girozentrale sold out of Amedisys (AMED) in Q1 2022, closing a stake of 4,579 shares — an estimated $743K sold.

DekaBank Deutsche Girozentrale first reported a position in AMED in Q1 2018 and held it in 16 quarters. The position peaked at $4.61M in Q2 2021. 328 funds tracked by Wall St. Rank hold AMED as of Q1 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Amedisys position as of Q1 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 4,579 Amedisys shares in Q1 2022, an estimated $743K.
  • DekaBank Deutsche Girozentrale first reported a position in Amedisys in Q1 2018 and held it in 16 quarters.
  • DekaBank Deutsche Girozentrale's Amedisys position peaked at $4.61M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Amedisys as of Q1 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2022, filed 28 Apr 2022.